CRISPR Therapeutics (NASDAQ:CRSP) Given New $90.00 Price Target at Citigroup

CRISPR Therapeutics (NASDAQ:CRSP) had its price objective increased by stock analysts at Citigroup from $88.00 to $90.00 in a note issued to investors on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the stock. Citigroup‘s price target suggests a potential upside of 73.81% from the company’s current price.

Several other research firms have also issued reports on CRSP. William Blair upgraded CRISPR Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 23rd. Wall Street Zen upgraded shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. UBS Group assumed coverage on shares of CRISPR Therapeutics in a research note on Thursday, October 15th. They set a “neutral” rating and a $52.00 price objective on the stock. Wells Fargo & Company reduced their price objective on shares of CRISPR Therapeutics from $75.00 to $70.00 and set an “equal weight” rating on the stock in a research note on Wednesday. Finally, The Goldman Sachs Group restated a “neutral” rating and set a $55.00 price objective on shares of CRISPR Therapeutics in a report on Thursday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $66.12.

CRISPR Therapeutics Trading Up 3.6%

CRSP stock traded up $1.79 during midday trading on Wednesday, reaching $51.78. The company’s stock had a trading volume of 1,388,191 shares, compared to its average volume of 1,718,181. CRISPR Therapeutics has a 52 week low of $44.12 and a 52 week high of $63.45. The stock has a market cap of $5.01 billion, a PE ratio of -10.92 and a beta of 1.92. The company has a quick ratio of 17.85, a current ratio of 17.85 and a debt-to-equity ratio of 0.34. The business’s 50-day simple moving average is $53.86 and its 200-day simple moving average is $52.85.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Monday, November 2nd. The company reported ($1.15) EPS for the quarter, missing the consensus estimate of ($1.06) by ($0.09). The business had revenue of $12.67 million for the quarter, compared to the consensus estimate of $14.75 million. CRISPR Therapeutics had a negative net margin of 1,812.07% and a negative return on equity of 24.96%. The company’s revenue for the quarter was up 1311.1% on a year-over-year basis. As a group, sell-side analysts expect that CRISPR Therapeutics will post -4.44 EPS for the current year.

Insiders Place Their Bets

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 47,837 shares of CRISPR Therapeutics stock in a transaction dated Monday, October 19th. The stock was sold at an average price of $49.78, for a total transaction of $2,381,325.86. Following the transaction, the chief executive officer directly owned 311,899 shares in the company, valued at approximately $15,526,332.22. The trade was a 13.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Ali Behbahani sold 13,679 shares of the business’s stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $57.09, for a total value of $780,934.11. Following the completion of the transaction, the director directly owned 16,637 shares of the company’s stock, valued at approximately $949,806.33. The trade was a 45.12% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 93,558 shares of company stock worth $4,881,663. 5.20% of the stock is owned by corporate insiders.

Institutional Trading of CRISPR Therapeutics

Large investors have recently bought and sold shares of the business. Canal Insurance CO acquired a new stake in shares of CRISPR Therapeutics in the first quarter valued at about $1,670,000. Quantinno Capital Management LP boosted its position in CRISPR Therapeutics by 613.5% during the first quarter. Quantinno Capital Management LP now owns 47,989 shares of the company’s stock valued at $2,283,000 after purchasing an additional 41,263 shares during the last quarter. KBC Group NV boosted its position in CRISPR Therapeutics by 3,999.9% during the first quarter. KBC Group NV now owns 116,847 shares of the company’s stock valued at $5,558,000 after purchasing an additional 113,997 shares during the last quarter. Raiffeisen Bank International AG bought a new position in CRISPR Therapeutics in the second quarter valued at approximately $1,127,000. Finally, Shah Wealth Advisors LLC bought a new position in CRISPR Therapeutics in the second quarter valued at approximately $3,767,000. 69.20% of the stock is owned by institutional investors.

CRISPR Therapeutics News Summary

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: CRISPR Therapeutics said Phase 1/2 data for zugo-cel in relapsed or refractory large B-cell lymphoma will be presented orally at the ASH meeting in December. The presentation puts a clinical-stage program in the spotlight, though the announcement did not disclose new results. Article: CRISPR Therapeutics to Present Clinical Data from Zugo-cel
• Positive Sentiment: CASGEVY generated $99 million in third-quarter sales, up 30% from the prior quarter and nearly sixfold year over year. The company also cited new pediatric approvals in the U.K., UAE and Bahrain, supporting the therapy’s commercial expansion. Article: Third-quarter business update and results
• Neutral Sentiment: Pipeline developments included FDA RMAT designations for CTX310 and completion of enrollment in a Phase 2 CTX611 study. These milestones may support longer-term prospects, but do not yet establish commercial success. Article: Third-quarter business update and results
• Negative Sentiment: CRISPR reported a third-quarter loss of $1.15 per share, wider than the $1.06 expected, while reported revenue of $12.67 million also missed consensus of $14.75 million. The earnings shortfall tempers the positive CASGEVY sales figures. Article: CRSP’s Q3 Loss Wider Than Expected
• Negative Sentiment: Brookline Capital Markets modestly lowered its 2028–2030 earnings-per-share forecasts, a small reduction in its longer-term outlook.

About CRISPR Therapeutics

CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing transformative gene-based medicines using CRISPR/Cas9 gene-editing technology. The company’s research programs are designed to address genetic diseases by precisely modifying DNA in cells, with applications across hematology, immunology, oncology, regenerative medicine and cardiovascular disease.

Its lead commercial product is CASGEVY, an autologous cell therapy developed in collaboration with Vertex Pharmaceuticals.